1 active not recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Apollomics Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) APL-101, Osimertinib - Metastatic Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | Washington University School of Medicine | 27 | 2022-01-18 | 2026-01-20 |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors APL-101 Oral Capsules - Solid Tumors, Advanced Cancer | Phase 2 | Recruiting | Apollomics Inc. | 497 | 2017-09-27 | 2025-06-27 |
Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Glioblastoma (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1) · Thyroid Neoplasms (1)
osimertinib (1)
United States (2) · Australia (1) · Canada (1) · France (1) · Hungary (1) · Italy (1) · Russia (1) · Singapore (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Anjali Rohatgi, M.D., Ph.D. (1) · Mythili Sangem (1)